🏛️ Company factsSEC filings + FINRA official data
Annual revenue $29.4B · latest quarter up 10.2% YoY · profitable (FY net income $8.5B) · short activity above its recent average — bears adding.
FY revenue
$29.4B
2025-12
Latest Q YoY
+10.2%
Gross margin
24%
FY net income
$8.5B
Diluted EPS
$6.84
Short volume
57.3%
20d avg 36.5% · shorts building
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability Medium · 63/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026-$6.75 vs -$7.07+4.53%
- Mar 2026$2.03 vs $1.89+7.41%
- Dec 2025$1.86 vs $1.83+1.64%
- Sep 2025$2.47 vs $2.15+14.88%
The takeaway
This company habitually beats by +7.1% — the next report has to clear that bar to count as good news.
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
1 direct · 0 2nd-order · 0 thematicRanked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)
Trodelvy in breast cancer faces potential substitution and share erosion from the newly approved therapy.
Also named: AZN · PFE · LLY
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
7 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →